NovMetaPharma노브메타파마
229500 · KONEX · ₩229500 · 노브메타파마
- Market cap
- ₩44B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−78.3% from the high
₩3,295Today: ₩3,295 – ₩3,450₩15,600
Returns
- 1W−1.9%
- 1M−36.0%
- 3M−36.1%
- 6M−63.2%
- YTD−74.9%
- 1Y−75.8%
- Volume today
- 1,447
- 0.2× the 20-day average
- Traded today
- ₩4.9M
- Listed shares
- 12,990,487
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-26.9% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
NovMetaPharma stock overview
NovMetaPharma (노브메타파마, KRX: 229500) is listed on KONEX, in the Biotech & Pharma sector. Novmetapharma is a Korean drug developer focused on metabolic diseases and inflammation and fibrosis, aiming to out-license its candidates to global pharmaceutical companies. Its shares closed at ₩3,385 on Oct 27, 2026, up 2.73% on the day, giving it a market value of ₩44B.
Key facts
- Market cap
- ₩44B
- Sector
- Biotech & Pharma
- Latest price change
- +2.73%
- As of
- Oct 27, 2026
- Main business
- Novmetapharma is a Korean drug developer focused on metabolic diseases and inflammation and fibrosis, aiming to out-license its candidates to global pharmaceutical companies.
Quick answers about NovMetaPharma
- What does NovMetaPharma do?
- Novmetapharma is a Korean drug developer focused on metabolic diseases and inflammation and fibrosis, aiming to out-license its candidates to global pharmaceutical companies. Its pipeline includes NovDKD for diabetic kidney disease, treatments for muscle diseases such as FSHD and sarcopenia, and an idiopathic pulmonary fibrosis drug, and it also sells health functional foods (Pro-Z Gold) and raw materials such as C01 through distribution partners in Korea and the United States.
- What is the market cap of NovMetaPharma?
- The market capitalisation of NovMetaPharma was ₩44B at the close on Oct 27, 2026.
- Who are the largest shareholders of NovMetaPharma?
- According to the latest official filings, the largest reported holders are Song Mun-jin (32.88%, as of Feb 5, 2026).
- When is the next earnings report from NovMetaPharma?
- Korean companies rarely announce results dates in advance. Based on when NovMetaPharma filed the same report in past years, its next annual results is expected between Mar 14, 2027 and Mar 20, 2027.
Company profile
Novmetapharma is a Korean drug developer focused on metabolic diseases and inflammation and fibrosis, aiming to out-license its candidates to global pharmaceutical companies. Its pipeline includes NovDKD for diabetic kidney disease, treatments for muscle diseases such as FSHD and sarcopenia, and an idiopathic pulmonary fibrosis drug, and it also sells health functional foods (Pro-Z Gold) and raw materials such as C01 through distribution partners in Korea and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 노브메타파마
- Sector
- Biotech & Pharma
- CEO
- 황선욱, 정회윤 (각자 대표)
- Founded
- Nov 2010
- Listed
- Oct 2015
- Listed shares
- 12,990,487
- Fiscal year ends
- Month 12
- Website
- www.novmeta.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventOct 16, 2026
- Investor relations (IR) eventSep 28, 2026
- Investor relations (IR) eventJul 3, 2026
- Securities Issuance Results (Voluntary Disclosure)Jun 25, 2026
- Amended: Rights offering (paid-in capital increase) decisionJun 25, 2026
Titles in Korean until English translations are added.
Also known as: NovMetaPharma / 노브메타파마 / 229500 / KRX:229500
Source: KRX statistical information